Camurus Ab
Clinical trials sponsored by Camurus Ab, explained in plain language.
-
New injection could shrink livers and ease pain in rare disease
Disease control OngoingThis study tests a new long-acting octreotide injection (CAM2029) in 71 adults with symptomatic polycystic liver disease. Participants receive weekly or biweekly injections or a placebo for 53 weeks to see if the drug reduces liver size and improves symptoms like bloating, pain, …
Phase: PHASE2, PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated May 17, 2026 08:51 UTC
-
New shot could slow tumor growth in rare gut cancers
Disease control OngoingThis study tests a new, easy-to-use injectable drug (CAM2029) against standard treatments for people with advanced neuroendocrine tumors of the gut or pancreas. About 332 adults with tumors that cannot be removed by surgery will receive either the new drug or standard therapy. Th…
Phase: PHASE3 • Sponsor: Camurus AB • Aim: Disease control
Last updated May 14, 2026 12:02 UTC